Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.

Anti-thrombin, a member of the serpin family and an inhibitor of thrombin and blood coagulation factor Xa, was recently shown to inhibit angiogenesis and tumor growth. In the present study, we examined the expression of anti-thrombin in benign and malignant prostate gland. Using immunohistochemistry...

Full description

Bibliographic Details
Main Authors: Cao, Y, Lundwall, A, Gadaleanu, V, Lilja, H, Bjartell, A
Format: Journal article
Language:English
Published: 2002
_version_ 1826270927592095744
author Cao, Y
Lundwall, A
Gadaleanu, V
Lilja, H
Bjartell, A
author_facet Cao, Y
Lundwall, A
Gadaleanu, V
Lilja, H
Bjartell, A
author_sort Cao, Y
collection OXFORD
description Anti-thrombin, a member of the serpin family and an inhibitor of thrombin and blood coagulation factor Xa, was recently shown to inhibit angiogenesis and tumor growth. In the present study, we examined the expression of anti-thrombin in benign and malignant prostate gland. Using immunohistochemistry, anti-thrombin was found in prostate epithelium and stroma cells. Tissue microarrays of tumors (n = 112) and three different prostate cancer cell lines (PC-3, LNCaP, and DU-145) were all positive for anti-thrombin. Abundant expression in a population of prostatic tumor cells was further evidenced by in situ hybridization experiments. The immunostaining for anti-thrombin was confined to the cytoplasm, was most intense in Gleason grade 3 tumors, and in part overlapped with that of prostate-specific antigen. Western blotting of benign and malignant tissue homogenates revealed a predominant 58-kd anti-thrombin immunoreactive component. In vitro, anti-thrombin formed complexes more readily with human kallikrein 2, particularly in the presence of heparin, and less efficiently with prostate-specific antigen. Both complexes could be recognized by polyclonal and monoclonal IgGs against anti-thrombin. We conclude that anti-thrombin is widely expressed in prostate cancer but is gradually lost in tumors of high Gleason grade. Anti-thrombin may act as a local anti-angiogenic factor, the effect of which is partially lost in poorly differentiated prostatic tumors.
first_indexed 2024-03-06T21:48:33Z
format Journal article
id oxford-uuid:4a7382da-ac52-4992-8ffc-e91a63280f23
institution University of Oxford
language English
last_indexed 2024-03-06T21:48:33Z
publishDate 2002
record_format dspace
spelling oxford-uuid:4a7382da-ac52-4992-8ffc-e91a63280f232022-03-26T15:37:33ZAnti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4a7382da-ac52-4992-8ffc-e91a63280f23EnglishSymplectic Elements at Oxford2002Cao, YLundwall, AGadaleanu, VLilja, HBjartell, AAnti-thrombin, a member of the serpin family and an inhibitor of thrombin and blood coagulation factor Xa, was recently shown to inhibit angiogenesis and tumor growth. In the present study, we examined the expression of anti-thrombin in benign and malignant prostate gland. Using immunohistochemistry, anti-thrombin was found in prostate epithelium and stroma cells. Tissue microarrays of tumors (n = 112) and three different prostate cancer cell lines (PC-3, LNCaP, and DU-145) were all positive for anti-thrombin. Abundant expression in a population of prostatic tumor cells was further evidenced by in situ hybridization experiments. The immunostaining for anti-thrombin was confined to the cytoplasm, was most intense in Gleason grade 3 tumors, and in part overlapped with that of prostate-specific antigen. Western blotting of benign and malignant tissue homogenates revealed a predominant 58-kd anti-thrombin immunoreactive component. In vitro, anti-thrombin formed complexes more readily with human kallikrein 2, particularly in the presence of heparin, and less efficiently with prostate-specific antigen. Both complexes could be recognized by polyclonal and monoclonal IgGs against anti-thrombin. We conclude that anti-thrombin is widely expressed in prostate cancer but is gradually lost in tumors of high Gleason grade. Anti-thrombin may act as a local anti-angiogenic factor, the effect of which is partially lost in poorly differentiated prostatic tumors.
spellingShingle Cao, Y
Lundwall, A
Gadaleanu, V
Lilja, H
Bjartell, A
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
title Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
title_full Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
title_fullStr Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
title_full_unstemmed Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
title_short Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
title_sort anti thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate specific antigen and human glandular kallikrein 2
work_keys_str_mv AT caoy antithrombinisexpressedinthebenignprostaticepitheliumandinprostatecancerandiscapableofformingcomplexeswithprostatespecificantigenandhumanglandularkallikrein2
AT lundwalla antithrombinisexpressedinthebenignprostaticepitheliumandinprostatecancerandiscapableofformingcomplexeswithprostatespecificantigenandhumanglandularkallikrein2
AT gadaleanuv antithrombinisexpressedinthebenignprostaticepitheliumandinprostatecancerandiscapableofformingcomplexeswithprostatespecificantigenandhumanglandularkallikrein2
AT liljah antithrombinisexpressedinthebenignprostaticepitheliumandinprostatecancerandiscapableofformingcomplexeswithprostatespecificantigenandhumanglandularkallikrein2
AT bjartella antithrombinisexpressedinthebenignprostaticepitheliumandinprostatecancerandiscapableofformingcomplexeswithprostatespecificantigenandhumanglandularkallikrein2